Pharvaris

Yahoo Finance • last month

Pharvaris stock price target lowered to $52 by Citizens JMP

Investing.com - Citizens JMP lowered its price target on Pharvaris B.V. (NASDAQ:PHVS) to $52.00 from $55.00 on Wednesday, while maintaining a Market Outperform rating on the stock. Currently trading at $21.09, the company shows a strong fi... Full story

Yahoo Finance • last month

Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress

PHARVARIS NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) REPORTS Q2 2025 EARNINGS: WIDER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Pharvaris NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) reported a seco... Full story

Yahoo Finance • 2 months ago

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with... Full story

Yahoo Finance • 2 months ago

Pharvaris prices $175M securities offering

Pharvaris (NASDAQ:PHVS [https://seekingalpha.com/symbol/PHVS]) priced [https://seekingalpha.com/pr/20174484-pharvaris-announces-pricing-of-upsized-175-million-public-offering-of-ordinary-shares-and-pre]an underwritten offering of 8.25 mill... Full story

Yahoo Finance • 3 months ago

Pharvaris stock awaits pivotal HAE therapy data as BofA reiterates Underperform

Investing.com - BofA Securities has reiterated its Underperform rating and $14.00 price target on Pharvaris B.V. (NASDAQ:PHVS), currently trading at $18.68, as the company announced updated timelines for its hereditary angioedema (HAE) the... Full story

Yahoo Finance • 3 months ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediate... Full story

Yahoo Finance • 3 months ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-me... Full story

Yahoo Finance • 3 months ago

NodThera Announces Appointment of Elisabeth Björk as Board Member

NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commen... Full story

Yahoo Finance • 3 months ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-me... Full story

Yahoo Finance • 4 months ago

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-me... Full story

Yahoo Finance • 4 months ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant po... Full story

Yahoo Finance • 4 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-med... Full story

Yahoo Finance • 4 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the... Full story

Yahoo Finance • 6 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucric... Full story

Yahoo Finance • 6 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-m... Full story

Yahoo Finance • 7 months ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported imp... Full story

Yahoo Finance • 7 months ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-m... Full story

Yahoo Finance • 2 years ago

Pharvaris to Present at the GA²LEN UCARE Conference 2023

ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced th... Full story

Yahoo Finance • 2 years ago

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced th... Full story

Yahoo Finance • 2 years ago

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

ZUG, Switzerland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced th... Full story